Nobelpharma
Quick facts
Phase 3 pipeline
- IKH-01 · Diabetes
IKH-01 is a small molecule that targets the SGLT2 receptor. - Norethisterone,Ethinylestradiol · Women's Health
Norethisterone is a progestogen that acts as an agonist of the progesterone receptor, while ethinylestradiol is an estrogen that acts as an agonist of the estrogen receptor. - NPC-01 · Diabetes
NPC-01 is a small molecule that targets the SGLT2 receptor. - NPC-02 · Diabetes
NPC-02 is a small molecule that targets the SGLT2 receptor. - NPC-07 for oral administration · Diabetes
NPC-07 is a small molecule that targets the SGLT2 receptor. - NPC-09 · Diabetes
NPC-09 is a small molecule that targets the SGLT2 receptor. - NPC-12Y gel · Dermatology/Wound Care
NPC-12Y is a topical gel formulation designed to promote wound healing and tissue regeneration through growth factor delivery. - NPC-15 · Diabetes
NPC-15 is a small molecule that targets the SGLT2 receptor. - NPC-16 Continuous Dosing Regimen Group · Immunology
NPC-16 is a small molecule that targets the sphingosine-1-phosphate receptor 1 (S1PR1) to modulate immune cell trafficking. - NPC-16 Standard Dosing Regimen Group · Immunology
NPC-16 is a small molecule that targets the sphingosine-1-phosphate receptor 1 (S1PR1) to modulate immune responses.
Phase 2 pipeline
Phase 1 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about Nobelpharma
What is Nobelpharma's pipeline?
Nobelpharma has 10 drugs in Phase 3, 4 in Phase 2, 2 in Phase 1. Late-stage candidates include IKH-01, Norethisterone,Ethinylestradiol, NPC-01, NPC-02.
Related
- Sector hub: All tracked pharma companies